<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28074">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741245</url>
  </required_header>
  <id_info>
    <org_study_id>0653H-832</org_study_id>
    <secondary_id>163336</secondary_id>
    <nct_id>NCT02741245</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)</brief_title>
  <official_title>A Phase III, Randomized, Active Comparator-controlled, Clinical Trial to Study the Efficacy and Safety of MK-0653H in Japanese Patients With Hypercholesterolemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety and tolerability of 2 dose levels of
      MK-0653H in Japanese participants. The primary hypotheses are that the administration of
      MK-0653H is safe and tolerable and that MK-0653H is superior to single entity of Ezetimibe
      and Rosuvastatin in percent reduction from baseline in low-density lipoprotein-cholesterol
      (LDL-C) after 12 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline in LDL-C</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Adverse Event</measure>
    <time_frame>up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who are Discontinued from the Study Due to Adverse Event</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">321</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 2.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 5.0 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg+ Rosuvastatin 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg+ Rosuvastatin 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10 mg</intervention_name>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg+ Rosuvastatin 2.5 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg+ Rosuvastatin 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 2.5 mg</intervention_name>
    <arm_group_label>Rosuvastatin 2.5 mg</arm_group_label>
    <arm_group_label>Rosuvastatin 5.0 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg+ Rosuvastatin 2.5 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg+ Rosuvastatin 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Ezetimibe</intervention_name>
    <arm_group_label>Rosuvastatin 2.5 mg</arm_group_label>
    <arm_group_label>Rosuvastatin 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Rosuvastatin</intervention_name>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Rosuvastatin 2.5 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg+ Rosuvastatin 2.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese

          -  Outpatient with hypercholesterolemia

          -  Female participant who is of reproductive potential has to agree to remain abstinent
             or use (or partner use) two acceptable methods of birth control from date of signed
             informed consent to the 14 days after the last dose of study drug

          -  Will maintain a stable diet that is consistent with the Japan Atherosclerosis Society
             Guideline 2012 (JAS 2012) for prevention of atherosclerotic cardiovascular diseases
             for the duration of the study

        Exclusion Criteria:

          -  Uncontrolled hypertension (treated or untreated)

          -  Uncontrolled type 1 or type 2 diabetes mellitus

          -  History of coronary artery disease (CAD), CAD-equivalent disease

          -  Familial hypercholesterolemia or has undergone LDL apheresis

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins

          -  Has had a gastrointestinal tract bypass, or other significant intestinal
             malabsorption

          -  History of cancer within the past 5 years (except for successfully treated
             dermatological basal cell or squamous cell carcinoma or in situ cervical cancer)

          -  Human Immunodeficiency Virus (HIV) positive

          -  History of drug/ alcohol abuse within the past 5 years or psychiatric illness not
             adequately controlled and stable on pharmacotherapy

          -  Consumes more than 25 g of alcohol per day

          -  Currently following an excessive weight reduction diet

          -  Currently engages in a vigorous exercise regimen (e.g.; marathon training, body
             building training etc.) or intends to start training during the study

          -  Hypersensitivity or intolerance to Ezetimibe or Rosuvastatin

          -  Myopathy or rhabdomyolysis with Ezetimibe or any statin

          -  Pregnant or lactating

          -  Taking any other investigational drugs and/or has taken any investigational drugs
             within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>April 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
